Health Care Equipment

EKSO Bionics

EKSO Bionics released FY2026 Q1 earnings on April 28 (EST), actual revenue USD 2.141 M (forecast USD 4.55 M), actual EPS USD -2.04 (forecast USD -0.23)

EKSO Bionics released FY2025 Annual Earnings on February 23 (EST), actual revenue USD 12.8 M (forecast USD 14.71 M), actual EPS USD -4.91 (forecast USD -2.17)

EKSO Bionics released FY2025 Q4 earnings on February 23 (EST), actual revenue USD 3.14 M (forecast USD 5.026 M), actual EPS USD -1.4578 (forecast USD -0.35)

Applied Digital Cloud Acquired by Ekso Bionics Holdings

Applied Digital and EKSO Bionics Merge to Form AI Acceleration Platform ChronoScale

EKSO Bionics released FY2025 9 Months earnings on October 28 (EST), actual revenue USD 9.659 M, actual EPS USD -3.4936

EKSO Bionics released FY2025 Q3 earnings on October 28 (EST), actual revenue USD 4.227 M (forecast USD 4.157 M), actual EPS USD -0.5431 (forecast USD -0.965)

Ekso Bionics Releases Investor Presentation

EKSO Bionics released FY2025 Q2 earnings on July 28 After-Market EST, actual revenue USD 2.057 M (forecast USD 4.313 M), actual EPS USD -1.2426 (forecast USD -1.35)

EKSO Bionics released FY2025 Semi-Annual earnings on July 28 After-Market (EST), actual revenue USD 5.432 M, actual EPS USD -3.0061

EKSO Bionics to Release FY2025 Q2 Earnings on July 28 After-Market (EST), Forecast Revenue USD 4.313M, EPS USD -1.35

CITIC Securities Research Outlines Positive Outlook for Exoskeleton Robotics

Ekso Bionics announces reverse stock split effective date update to June 2, 2025

HC Wainwright Maintains Ekso Bionics Rating but Cuts Price Target

EKSO Bionics released FY2025 Q1 earnings on May 5 After-Market EST, actual revenue USD 3.375 M (forecast USD 4.625 M), actual EPS USD -1.7077 (forecast USD -1.65)

Ekso Bionics Announces Q1 2025 Financial and Business Results

EKSO Bionics to release FY2025 Q1 earnings report on May 5 After-Market EST, forecast revenue USD 4.625 M, EPS USD -0.11

Ekso Bionics Holdings Reports Quarterly Financial Results with Adjusted Loss of 14 Cents per Share

EKSO Bionics released FY2024 earnings on March 3 After-Market EST, actual revenue USD 17.93 M (forecast USD 17.87 M), actual EPS USD -8.43 (forecast USD -7.5)

EKSO Bionics released FY2024 Q4 earnings on March 3 After-Market EST, actual revenue USD 5.09 M (forecast USD 5.05 M), actual EPS USD -2.0777 (forecast USD -1.2)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Ticker Change

代码变更

From 2026.05.05 (EST) changed to CHRN

EKSO

HUMN

CHRN

Hypershell, a Chinese startup, is developing lightweight exoskeletons aimed at enhancing human capability for outdoor and everyday use. By combining motors and sensors, their products assist with walking and climbing, focusing on aesthetics and ease of use to encourage consumer adoption. Targeting outdoor enthusiasts initially, Hypershell plans to expand into North America and Europe. The company faces challenges in reducing costs and validating scalable applications, with current prices ranging from $899 to $1,999. As technology advances, the transition to mainstream consumer use is expected to be gradual, emphasizing iterative development and user feedback.

TechNode

Roundhill Humanoid Robotics ETF

ChronoScale

Betting on human augmentation, will lightweight exoskeletons go mainstream?

Earnings Watch

EKSO Bionics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.141 M

SBIO

Insider activity at EKSO BIONICS on March 20, 2026, saw COO Jason C Jones and CFO Jerome Wong each purchase 1,308 shares, indicating strong executive confidence. However, the company faces significant IP risks, including trade-secret infringement and dependence on co-owned patents, which could impact future innovations. Analysts view EKSO stock as Neutral due to ongoing losses and cash burn, despite some positive technical indicators. The current market cap is $37.06M, with a year-to-date price performance of 20.37%.

Tip Ranks

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Top EKSO BIONICS Insiders Make Bold Moves With Fresh Share Purchases

EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M

ANIK

NBSE.ESC

Eikon Therapeutics, Inc is set to IPO on February 5, 2026, on NASDAQ under the ticker EIKN. The shares are expected to be priced between $16.00 and $18.00 each, with a 180-day insider lock-up period ending on August 4, 2026. The company focuses on developing innovative medicines for serious unmet medical needs.

fidelity

Anika Therap

ESC NEUBASE THERAPEUTI

Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow

Ekso Bionics (EKSO) announced a private placement of $5.8 million on January 20, 2026, involving 5,852 shares of Series B preferred stock and warrants for up to 360,000 common shares. Each preferred share is valued at $1,000 and can be converted into common shares at any time.

Direxion S&P Biotech Bear 3X

Ekso Bionics prices $5.8M private placement

Investors are urged to reach out to the company promptly due to a potential time constraint to protect their rights. A renowned law firm, Halper Sadeh LLC based in New York, as of January 13, 2026, is currently looking into multiple companies for suspected infringements of federal securities laws and/or breaches.

Unusual Whales

Halper Sadeh LLC urges VTYX, SNCY, EKSO shareholders to discuss rights; investigating potential violations. Act now. Jan. 13, 2026. 118 characters.

EKSO Bionics(EKSO.US)